Cargando…

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus

Management of systemic lupus erythematosus (SLE) represents a fascinating, emerging field. Research has recently provided us with a better understanding of the immunologic alterations of SLE, leading to the creation of immunomodulatory agents designed to disrupt specific cell targets and pro-inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Rayes, Hanan, Touma, Zahi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242126/ https://www.ncbi.nlm.nih.gov/pubmed/25429203 http://dx.doi.org/10.2147/DDDT.S49778

Ejemplares similares

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease
por: Al Rayes, Hanan, et al.
Publicado: (2017)

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2006)

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
por: Daridon, Capucine, et al.
Publicado: (2010)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus
por: Cogollo, Estafania, et al.
Publicado: (2015)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]
Publicado: (2015)

Intraindividual Change in Cognitive Function Among Adults With Systemic Lupus Erythematosus: A Markov Analysis Over 7 Years
por: Perera, Stefan, et al.
Publicado: (2023)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
por: Strand, Vibeke, et al.
Publicado: (2020)

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
por: Wallace, Daniel J, et al.
Publicado: (2014)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
por: Lenert, Aleksander, et al.
Publicado: (2017)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

The dynamic relationship of gut microbiota with sex hormones in systemic lupus erythematosus
por: Katrib, Marcel, et al.
Publicado: (2023)

Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
por: Collins, Christopher E., et al.
Publicado: (2020)

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
por: Mai, Lloyd, et al.
Publicado: (2021)

Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review
por: Mendelsohn, Sierra, et al.
Publicado: (2021)

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus
por: Medina-Rosas, Jorge, et al.
Publicado: (2015)

Apolipoprotein E Gene Polymorphisms in Saudi Patients with Systemic Lupus Erythematosus
por: Al-Rayes, Hannan, et al.
Publicado: (2016)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)

Immune Profiling and Precision Medicine in Systemic Lupus Erythematosus
por: Nagafuchi, Yasuo, et al.
Publicado: (2019)

Systemic lupus erythematosus
por: Manson, Jessica J, et al.
Publicado: (2006)

Treatment of Bullous Systemic Lupus Erythematosus
por: Duan, Lihua, et al.
Publicado: (2015)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
por: Huo, Rongxiu, et al.
Publicado: (2023)

Oxidative stress and its biomarkers in systemic lupus erythematosus
por: Shah, Dilip, et al.
Publicado: (2014)

Changing paradigms in the treatment of systemic lupus erythematosus
por: Fanouriakis, Antonis, et al.
Publicado: (2019)

Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus
por: Accapezzato, Daniele, et al.
Publicado: (2023)

Systemic Lupus Erythematosus
por: Peng, Stanford
Publicado: (1993)

Herpes zoster in SLE: prevalence, incidence and risk factors
por: Kwan, Andrew, et al.
Publicado: (2022)

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort
por: Fung, William A., et al.
Publicado: (2017)

Pregnancy Associated with Systemic Lupus Erythematosus: Immune Tolerance in Pregnancy and Its Deficiency in Systemic Lupus Erythematosus—An Immunological Dilemma
por: Gluhovschi, Cristina, et al.
Publicado: (2015)

Quality of life in systemic lupus erythematosus and its measurement
por: Olesińska, Marzena, et al.
Publicado: (2018)

Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus
por: Yuen, Kimberley, et al.
Publicado: (2021)

Complement and systemic lupus erythematosus
por: Walport, Mark J
Publicado: (2002)

Systemic lupus erythematosus and thrombosis
por: Bazzan, Mario, et al.
Publicado: (2015)

Systemic Lupus Erythematosus and Immunodeficiency
por: Chan, Shirley Chiu Wai, et al.
Publicado: (2021)

Immunological pathogenesis and treatment of systemic lupus erythematosus
por: Pan, Lu, et al.
Publicado: (2019)

State‐of‐the‐art treatment of systemic lupus erythematosus
por: Tanaka, Yoshiya
Publicado: (2020)

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
por: Touma, Zahi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f1ho8lrbmsu7cmtc92i8b0a058